Nidanilimab (Nadunolimab)
Product Specifications
UNSPSC Description
Nidanilimab (CAN04) is a fully humanized monoclonal anti-IL1RAP antibody with a Kd value of 1.10 pM. Nidanilimab blocks IL1α and IL1β signaling and stimulates the immune system to destroy tumour cells. Nidanilimab can be used in research of non-small lung cancer (NSCLC) and pancreatic ductal adenocarcinoma (PDAC) [1][2].
Target Antigen
Interleukin Related
Type
Inhibitory Antibodies
Related Pathways
Immunology/Inflammation
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/nidanilimab-nadunolimab.html
Purity
99.90
Solubility
10 mM in DMSO
Smiles
[Nidanilimab (Nadunolimab)]
References & Citations
[1]Millrud CR, et, al. The anti-IL1RAP antibody CAN04 increases tumor sensitivity to platinum-based chemotherapy.|[2]Rydberg Millrud C, et, al. Blockade of IL-1α and IL-1β signaling by the anti-IL1RAP antibody nadunolimab (CAN04) mediates synergistic anti-tumor efficacy with chemotherapy. Cancer Immunol Immunother. 2022 Aug 29.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Product Datasheet
http://file.medchemexpress.com/batch_PDF/HY-P99379/Nidanilimab-Nadunolimab-DataSheet-MedChemExpress.pdf
Product MSDS
http://file.medchemexpress.com/batch_PDF/HY-P99379/Nidanilimab-Nadunolimab-SDS-MedChemExpress.pdf
Clinical Information
Phase 2
CAS Number
2171061-85-9
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
